THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL
Open Access
- 29 September 2017
- journal article
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 55 (4), 351-359
- https://doi.org/10.14412/1995-4484-2017-351-359
Abstract
The Russian biotechnological company «BIOCAD» has designed a chimeric monoclonal antibody against CD20 (BCD-020, Acellbia®) that is a biosimilar of rituximab (RTM; MabThera®, F. Hoffmann-La Roche Ltd., Switzerland). In recent years, there has been evidence that RTM can be used at lower doses than those given in the standard recommendations and instructions for the use of this drug. This serves as the basis for the BCD-020-4/ALTERRA (ALTErnative Rituximab regimen in Rheumatoid Arthritis) trial, the objective of which was to investigate the efficiency and safety of using Acellbia® (at a dose of 600 mg twice at a 2-week interval) as the first biological agent (BA) for methotrexate (MTX)-resistant active rheumatoid arthritis (RA). The investigation enrolled 159 patients aged 18 to 80 years with active RA. After 24 weeks 65.7 and 29.4% of patients achieved 20% improvement by the American College of Rheumatology (ACR) criteria in the Acellbia® + MTX and placebo (PL) + MTX groups, respectively (pKeywords
This publication has 61 references indexed in Scilit:
- The role of autoantibodies in the pathophysiology of rheumatoid arthritisSeminars in Immunopathology, 2017
- B cell autoimmunity and bone damage in rheumatoid arthritisReumatismo, 2016
- Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritisNature Reviews Rheumatology, 2016
- Rheumatoid arthritisThe Lancet, 2016
- Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factorThe Journal of Experimental Medicine, 2016
- Rituximab for Rheumatoid ArthritisRheumatology and Therapy, 2015
- B cells and rheumatoid factors in autoimmunityInternational Journal of Rheumatic Diseases, 2015
- B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease BiomarkersBioMed Research International, 2014
- To B or Not to B the Conductor of Rheumatoid Arthritis OrchestraClinical Reviews in Allergy & Immunology, 2012
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994